blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3209328

EP3209328 - INHIBITORS OF LACTATE TRANSPORTERS FOR USE IN THE TREATMENT OF INFLAMMATORY DISEASES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  08.07.2022
Database last updated on 15.06.2024
FormerThe patent has been granted
Status updated on  30.07.2021
FormerGrant of patent is intended
Status updated on  14.03.2021
FormerExamination is in progress
Status updated on  22.06.2018
FormerRequest for examination was made
Status updated on  28.07.2017
FormerThe international publication has been made
Status updated on  28.04.2017
Most recent event   Tooltip14.06.2024Lapse of the patent in a contracting state
New state(s): TR		published on 17.07.2024 [2024/29]
Applicant(s)For all designated states
The University Of Birmingham
Edgbaston
Birmingham B15 2TT / GB
[2022/11]
Former [2017/35]For all designated states
Queen Mary University of London
Mile End Road
London E1 4NS / GB
Inventor(s)01 / MAURO, Claudio
Centre for Biochemical Pharmacology
William Harvey Research Institute
Heart Centre
Charterhouse Square
London EC1M 6BQ / GB
02 / HAAS, Robert
Centre for Biochemical Pharmacology
William Harvey Research Institute
Heart Centre
Charterhouse Square
London EC1M 6BQ / GB
03 / MARELLI-BERG, Federica
Centre for Biochemical Pharmacology
William Harvey Research Institute
Heart Centre
Charterhouse Square
London EC1M 6BQ / GB
 [2017/35]
Representative(s)Bassil, Nicholas Charles, et al
Kilburn & Strode LLP
Lacon London
84 Theobalds Road
London WC1X 8NL / GB
[2021/35]
Former [2017/35]Bassil, Nicholas Charles, et al
Kilburn & Strode LLP
20 Red Lion Street
London WC1R 4PJ / GB
Application number, filing date15791340.120.10.2015
[2017/35]
WO2015GB53125
Priority number, dateGB2014001862620.10.2014         Original published format: GB 201418626
[2017/35]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016063037
Date:28.04.2016
Language:EN
[2016/17]
Type: A1 Application with search report 
No.:EP3209328
Date:30.08.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 28.04.2016 takes the place of the publication of the European patent application.
[2017/35]
Type: B1 Patent specification 
No.:EP3209328
Date:01.09.2021
Language:EN
[2021/35]
Search report(s)International search report - published on:EP28.04.2016
ClassificationIPC:A61K39/395, C07K16/18, C07K16/28
[2017/35]
CPC:
C12N15/113 (EP,US); A61K39/395 (US); A61P1/04 (EP);
A61P17/06 (EP); A61P19/08 (EP); A61P29/00 (EP);
A61P35/00 (EP); A61P37/02 (EP); A61P43/00 (EP);
A61P9/10 (EP); C07K16/18 (EP,US); C07K16/28 (EP,US);
A61K2039/505 (EP,US); C07K2317/76 (EP,US); C12N2310/14 (EP,US);
C12N2310/531 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/35]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:HEMMER VON LACTATTRANSPORTERN ZUR VERWENDUNG BEI DER BEHANDLUNG VON ENTZÜNDLICHEN ERKRANKUNGEN[2017/35]
English:INHIBITORS OF LACTATE TRANSPORTERS FOR USE IN THE TREATMENT OF INFLAMMATORY DISEASES[2017/35]
French:INHIBITEURS DE TRANSPORTEURS DE LACTATE DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE MALADIES INFLAMMATOIRES[2017/35]
Entry into regional phase27.04.2017National basic fee paid 
27.04.2017Designation fee(s) paid 
27.04.2017Examination fee paid 
Examination procedure27.04.2017Examination requested  [2017/35]
27.04.2017Date on which the examining division has become responsible
29.11.2017Amendment by applicant (claims and/or description)
21.06.2018Despatch of a communication from the examining division (Time limit: M04)
01.10.2018Reply to a communication from the examining division
14.02.2019Despatch of a communication from the examining division (Time limit: M06)
26.07.2019Reply to a communication from the examining division
03.02.2020Despatch of a communication from the examining division (Time limit: M06)
11.08.2020Reply to a communication from the examining division
15.03.2021Communication of intention to grant the patent
26.07.2021Fee for grant paid
26.07.2021Fee for publishing/printing paid
26.07.2021Receipt of the translation of the claim(s)
Opposition(s)02.06.2022No opposition filed within time limit [2022/32]
Fees paidRenewal fee
27.10.2017Renewal fee patent year 03
29.10.2018Renewal fee patent year 04
29.10.2019Renewal fee patent year 05
14.10.2020Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU20.10.2015
AL01.09.2021
AT01.09.2021
CY01.09.2021
CZ01.09.2021
DK01.09.2021
EE01.09.2021
ES01.09.2021
FI01.09.2021
HR01.09.2021
IT01.09.2021
LT01.09.2021
LV01.09.2021
MC01.09.2021
MK01.09.2021
NL01.09.2021
PL01.09.2021
RO01.09.2021
RS01.09.2021
SE01.09.2021
SI01.09.2021
SK01.09.2021
SM01.09.2021
TR01.09.2021
IE20.10.2021
LU20.10.2021
BE31.10.2021
CH31.10.2021
LI31.10.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
IS01.01.2022
PT03.01.2022
[2024/29]
Former [2024/22]HU20.10.2015
AL01.09.2021
AT01.09.2021
CY01.09.2021
CZ01.09.2021
DK01.09.2021
EE01.09.2021
ES01.09.2021
FI01.09.2021
HR01.09.2021
IT01.09.2021
LT01.09.2021
LV01.09.2021
MC01.09.2021
MK01.09.2021
NL01.09.2021
PL01.09.2021
RO01.09.2021
RS01.09.2021
SE01.09.2021
SI01.09.2021
SK01.09.2021
SM01.09.2021
IE20.10.2021
LU20.10.2021
BE31.10.2021
CH31.10.2021
LI31.10.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
IS01.01.2022
PT03.01.2022
Former [2023/30]HU20.10.2015
AL01.09.2021
AT01.09.2021
CY01.09.2021
CZ01.09.2021
DK01.09.2021
EE01.09.2021
ES01.09.2021
FI01.09.2021
HR01.09.2021
IT01.09.2021
LT01.09.2021
LV01.09.2021
MC01.09.2021
NL01.09.2021
PL01.09.2021
RO01.09.2021
RS01.09.2021
SE01.09.2021
SI01.09.2021
SK01.09.2021
SM01.09.2021
IE20.10.2021
LU20.10.2021
BE31.10.2021
CH31.10.2021
LI31.10.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
IS01.01.2022
PT03.01.2022
Former [2023/29]HU20.10.2015
AL01.09.2021
AT01.09.2021
CZ01.09.2021
DK01.09.2021
EE01.09.2021
ES01.09.2021
FI01.09.2021
HR01.09.2021
IT01.09.2021
LT01.09.2021
LV01.09.2021
MC01.09.2021
NL01.09.2021
PL01.09.2021
RO01.09.2021
RS01.09.2021
SE01.09.2021
SI01.09.2021
SK01.09.2021
SM01.09.2021
IE20.10.2021
LU20.10.2021
BE31.10.2021
CH31.10.2021
LI31.10.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
IS01.01.2022
PT03.01.2022
Former [2022/48]AL01.09.2021
AT01.09.2021
CZ01.09.2021
DK01.09.2021
EE01.09.2021
ES01.09.2021
FI01.09.2021
HR01.09.2021
IT01.09.2021
LT01.09.2021
LV01.09.2021
MC01.09.2021
NL01.09.2021
PL01.09.2021
RO01.09.2021
RS01.09.2021
SE01.09.2021
SI01.09.2021
SK01.09.2021
SM01.09.2021
IE20.10.2021
LU20.10.2021
BE31.10.2021
CH31.10.2021
LI31.10.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
IS01.01.2022
PT03.01.2022
Former [2022/37]AL01.09.2021
AT01.09.2021
CZ01.09.2021
DK01.09.2021
EE01.09.2021
ES01.09.2021
FI01.09.2021
HR01.09.2021
IT01.09.2021
LT01.09.2021
LV01.09.2021
MC01.09.2021
NL01.09.2021
PL01.09.2021
RO01.09.2021
RS01.09.2021
SE01.09.2021
SI01.09.2021
SK01.09.2021
SM01.09.2021
LU20.10.2021
BE31.10.2021
CH31.10.2021
LI31.10.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
IS01.01.2022
PT03.01.2022
Former [2022/36]AL01.09.2021
AT01.09.2021
CZ01.09.2021
DK01.09.2021
EE01.09.2021
ES01.09.2021
FI01.09.2021
HR01.09.2021
IT01.09.2021
LT01.09.2021
LV01.09.2021
MC01.09.2021
NL01.09.2021
PL01.09.2021
RO01.09.2021
RS01.09.2021
SE01.09.2021
SI01.09.2021
SK01.09.2021
SM01.09.2021
LU20.10.2021
BE31.10.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
IS01.01.2022
PT03.01.2022
Former [2022/35]AL01.09.2021
AT01.09.2021
CZ01.09.2021
DK01.09.2021
EE01.09.2021
ES01.09.2021
FI01.09.2021
HR01.09.2021
LT01.09.2021
LV01.09.2021
MC01.09.2021
NL01.09.2021
PL01.09.2021
RO01.09.2021
RS01.09.2021
SE01.09.2021
SK01.09.2021
SM01.09.2021
LU20.10.2021
BE31.10.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
IS01.01.2022
PT03.01.2022
Former [2022/33]AL01.09.2021
AT01.09.2021
CZ01.09.2021
EE01.09.2021
ES01.09.2021
FI01.09.2021
HR01.09.2021
LT01.09.2021
LV01.09.2021
MC01.09.2021
NL01.09.2021
PL01.09.2021
RO01.09.2021
RS01.09.2021
SE01.09.2021
SK01.09.2021
SM01.09.2021
BE31.10.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
IS01.01.2022
PT03.01.2022
Former [2022/29]AL01.09.2021
AT01.09.2021
CZ01.09.2021
EE01.09.2021
ES01.09.2021
FI01.09.2021
HR01.09.2021
LT01.09.2021
LV01.09.2021
NL01.09.2021
PL01.09.2021
RO01.09.2021
RS01.09.2021
SE01.09.2021
SK01.09.2021
SM01.09.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
IS01.01.2022
PT03.01.2022
Former [2022/25]AT01.09.2021
CZ01.09.2021
EE01.09.2021
ES01.09.2021
FI01.09.2021
HR01.09.2021
LT01.09.2021
LV01.09.2021
NL01.09.2021
PL01.09.2021
RO01.09.2021
RS01.09.2021
SE01.09.2021
SK01.09.2021
SM01.09.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
IS01.01.2022
PT03.01.2022
Former [2022/24]AT01.09.2021
CZ01.09.2021
EE01.09.2021
ES01.09.2021
FI01.09.2021
HR01.09.2021
LT01.09.2021
LV01.09.2021
NL01.09.2021
PL01.09.2021
RO01.09.2021
RS01.09.2021
SE01.09.2021
SK01.09.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
IS01.01.2022
PT03.01.2022
Former [2022/21]AT01.09.2021
ES01.09.2021
FI01.09.2021
HR01.09.2021
LT01.09.2021
LV01.09.2021
PL01.09.2021
RS01.09.2021
SE01.09.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
Former [2022/10]ES01.09.2021
FI01.09.2021
HR01.09.2021
LT01.09.2021
LV01.09.2021
PL01.09.2021
RS01.09.2021
SE01.09.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
Former [2022/09]ES01.09.2021
FI01.09.2021
LT01.09.2021
RS01.09.2021
SE01.09.2021
BG01.12.2021
NO01.12.2021
Former [2022/08]ES01.09.2021
FI01.09.2021
LT01.09.2021
SE01.09.2021
BG01.12.2021
NO01.12.2021
Former [2022/07]LT01.09.2021
NO01.12.2021
Cited inInternational search[Y]US2004072746  (SULLIVAN MICHAEL [GB], et al) [Y] 5,6,8 * the whole document * * in particular, paragraphs 76, 115 and 242 *;
 [XY]WO2010089580  (ASTRAZENECA AB [SE], et al) [X] 2,4,7,9,11-13,15,17-20 * page 8 * [Y] 5,6,8;
 [X]KR20120123748  (WONKWANG UNIVERSITY CENTER FOR INDUSTRY-ACADEMY COOPERATION [KR]) [X] 2,4,9,11-13,15,17 * abstract *;
 [X]  - Anonymous, "NCT01791595 on 2013_10_07: ClinicalTrials.gov Archive", (20131007), URL: https://clinicaltrials.gov/archive/NCT01791595/2013_10_07, (20160115), XP055241680 [X] 2,4,7,9,11-13,15,17-20 * the whole document * * in particular, summary *
 [X]  - RENAUD LE FLOCH ET AL, "CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors", PROC NATL ACAD SCI, (20111004), vol. 108, no. 40, pages 16663 - 16668, XP055241679 [X] 2,4,7,15,17-20 * the whole document * * in particular, page 16664 *

DOI:   http://dx.doi.org/10.1073/pnas.1106123108
 [X]  - JOANNE R. DOHERTY ET AL, "Targeting lactate metabolism for cancer therapeutics", JOURNAL OF CLINICAL INVESTIGATION, US, (20130903), vol. 123, no. 9, doi:10.1172/JCI69741, ISSN 0021-9738, pages 3685 - 3692, XP055239122 [X] 2,4,7,15,17-20 * the whole document * * in particular, page 3688 *

DOI:   http://dx.doi.org/10.1172/JCI69741
 [X]  - CHICHE J ET AL, "The monocarboxylate transporter 1 (MCT1) and Hypoxia-induced MCT4 are key targets promoting tumor cell survival", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, OXFORD, GB, vol. 6, no. 9, doi:10.1016/S1359-6349(08)71267-9, ISSN 1359-6349, (20080701), page 24, (20080701), XP022833613 [X] 2,4,7,15,17 * abstract *

DOI:   http://dx.doi.org/10.1016/S1359-6349(08)71267-9
 [X]  - PIERRE SONVEAUX ET AL, "Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice", JOURNAL OF CLINICAL INVESTIGATION, US, (20081120), doi:10.1172/JCI36843, ISSN 0021-9738, XP055242099 [X] 2,4,7,15,17 * the whole document * * for instance, the abstract *

DOI:   http://dx.doi.org/10.1172/JCI36843
 [A]  - Robert Haas ET AL, "In the eye of the storm: T cell behavior in the inflammatory microenvironment", Am J Clin Exp Immunol, (20130615), pages 146 - 155, URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3714175/pdf/ajcei0002-0146.pdf, (20160112), XP055240437 [A] 1-20 * the whole document * * in particular, pages 150-151 *
 [A]  - CLARE M MURRAY ET AL, "Monocarboxylate transporter MCT1 is a target for immunosuppression", NATURE CHEMICAL BIOLOGY, GB, (20051201), vol. 1, no. 7, doi:10.1038/nchembio744, ISSN 1552-4450, pages 371 - 376, XP055241382 [A] 1-20 * the whole document * * in particular, pages 372-373 *

DOI:   http://dx.doi.org/10.1038/nchembio744
 [XP]  - ROBERT HAAS ET AL, "Lactate Regulates Metabolic and Pro-inflammatory Circuits in Control of T Cell Migration and Effector Functions", PLOS BIOLOGY, (20150716), vol. 13, no. 7, doi:10.1371/journal.pbio.1002202, page e1002202, XP055240411 [XP] 1-20 * the whole document *

DOI:   http://dx.doi.org/10.1371/journal.pbio.1002202
Examination   - GOPAL ET AL, "Cloning and functional characterization of human SMCT2 (SLC5A12) and expression pattern of the transporter in kidney", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - BIOMEMBRANES, ELSEVIER, AMSTERDAM, NL, (20071101), vol. 1768, no. 11, doi:10.1016/J.BBAMEM.2007.06.031, ISSN 0005-2736, pages 2690 - 2697, XP022338988

DOI:   http://dx.doi.org/10.1016/j.bbamem.2007.06.031
    - I Tamai ET AL, "Participation of a proton-cotransporter, MCT1, in the intestinal transpor of monocarboxylic acids", Biochemical and Biophysical Research Communications, (19950914), vol. 214, no. 2, pages 482 - 489, XP055484919
    - K. D. Rainsford, "Ibuprofen: pharmacology, efficacy and safety", INFLAMMOPHARMACOLOGY., NL, (20091121), vol. 17, no. 6, doi:10.1007/s10787-009-0016-x, ISSN 0925-4692, pages 275 - 342, XP055484915

DOI:   http://dx.doi.org/10.1007/s10787-009-0016-x
    - Seema Rao ET AL, "Targeted Delivery of Anti-CTLA-4 Antibody Downregulates T Cell Function in Vitro and in Vivo", CLINICAL IMMUNOLOGY, US, (20011101), vol. 101, no. 2, doi:10.1006/clim.2001.5119, ISSN 1521-6616, pages 136 - 145, XP055553868

DOI:   http://dx.doi.org/10.1006/clim.2001.5119
    - STANIMIROVIC DANICA ET AL, "Engineering and pharmacology of blood-brain barrier-permeable bispecific antibodies", ADVANCES IN PHARMACO, ELSEVIER, USA, (20140101), vol. 71, doi:10.1016/BS.APHA.2014.06.005, ISSN 1557-8925, pages 301 - 335, XP009188677

DOI:   http://dx.doi.org/10.1016/bs.apha.2014.06.005
    - C S D Roxburgh ET AL, "Cancer and systemic inflammation: treat the tumour and treat the host", British Journal of Cancer, GB, (20140218), vol. 110, no. 6, doi:10.1038/bjc.2014.90, ISSN 0007-0920, pages 1409 - 1412, XP055585294

DOI:   http://dx.doi.org/10.1038/bjc.2014.90
by applicantWO2012042270
    - JARMIN ET AL., J CLIN INVEST, (2008), vol. 118, pages 1154 - 1164
    - CROIA ET AL., ANN RHEUM DIS, (2013), vol. 72, pages 1559 - 1568
    - MONTERO-MELENDEZ ET AL., AM J PATHOL, (2011), vol. 179, pages 259 - 269
    - SCHUBERT ET AL., J IMMUNOL, (2004), vol. 172, pages 4503 - 4509
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.